Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, open label trial comparing the efficacy and safety of a basiliximab-based immunosuppressive regimen, immediate introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids versus basiliximab, delayed introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids in elderly patients with kidney transplants. [Ensayo multicéntrico, aleatorizado, abierto que compara la eficacia y seguridad de un régimen inmunosupresor basado en basiliximab, introducción inmediata de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides versus basiliximab, introducción retardada de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides en pacientes añosos trasplantados renales.]

X
Trial Profile

Multicenter, randomized, open label trial comparing the efficacy and safety of a basiliximab-based immunosuppressive regimen, immediate introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids versus basiliximab, delayed introduction of small doses of extended-release tacrolimus, mycophenolate sodium and steroids in elderly patients with kidney transplants. [Ensayo multicéntrico, aleatorizado, abierto que compara la eficacia y seguridad de un régimen inmunosupresor basado en basiliximab, introducción inmediata de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides versus basiliximab, introducción retardada de dosis reducidas de tacrolimus de liberación prolongada, micofenolato sódico y esteroides en pacientes añosos trasplantados renales.]

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Basiliximab; Corticosteroids; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2013 Status changed from recruiting to discontinued.
    • 14 Oct 2011 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top